Indian Health Board of Minneapolis

1315 East 24th Street Minneapolis, MN 55404



Clinical Quality Measures

2023 measurement year

Measure		Rating	Rate
		Kating	Nate
Adolescent Depression	PHQ-9 Utilization*	-	-
	Follow-up at Six Months	-	-
	Response at Six Months	-	-
ול	Remission at Six Months	-	-
scer	Follow-up at 12 Months	-	-
lole	Response at 12 Months	-	-
Ad	Remission at 12 Months	-	-
	PHQ-9 Utilization*	Average	74.60%
ion	Follow-up at Six Months	Below Expected	32.50%
ress	Response at Six Months	Expected	8.10%
Jepi	Remission at Six Months	Expected	4.10%
Adult Depression	Follow-up at 12 Months	Below Expected	22.80%
Ad	Response at 12 Months	Expected	8.10%
	Remission at 12 Months	Expected	3.30%
Adolescent Mental Health and/or Depression Screening*		Below	77.50%
Colorectal Cancer Screening		Below Expected	25.80%
Optimal Asthma Control - Adults		Below Expected	4.90%
Optin	nal Asthma Control - Children	Below Expected	8.20%
Optimal Diabetes Care HbA1c Control BP Control Daily Aspirin Use Statin Use Tobacco-Free		Below Expected Expected Below Expected Expected Below Expected Below Expected Below Expected	23.30% 58.10% 67.00% 98.90% 79.00% 64.10%
Optimal Vascular Care BP Control Daily Aspirin Use Statin Use Tobacco-Free		Expected Expected Expected Expected Below Expected	26.80% 75.60% 75.60% 95.10% 46.30%

⁻ Medical group not assigned to measure, did not have results, or did not meet reporting threshold

^{*}Measure not risk adjusted

Indian Health Board of Minneapolis

Healthcare Effectiveness Data and Information Set (HEDIS) Measures

2023 measurement year

Measure	Rating	Rate
Avoidance of Antibiotic Treatment in Acute Bronchitis/Bronchiolitis	-	-
Breast Cancer Screening	Average	73.20%
Cervical Cancer Screening	-	-
Childhood Immunization Status (Combo 10)	-	-
Chlamydia Screening in Women	Average	39.40%
Controlling High Blood Pressure	-	-
Diabetes Eye Exam	Below	38.30%
Immunizations for Adolescents (Combo 2)	-	-
Follow-up Care for Children Prescribed ADHD Medication	-	-
Osteoporosis Management in Women Who Had a Fracture	-	-
Use of Spirometry Testing in the Assessment and Diagnosis of COPD	-	-

⁻ Medical group not assigned to measure, did not have results, or did not meet reporting threshold

Ratings

Above: Medical group's actual rate is significantly above its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Average: Medical group's actual rate is not statistically different than its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Below: Medical group's actual rate is significantly below its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Total Cost of Care

2023 measurement year

Population	Monthly Average Cost	Rating	Higher/Lower than Average
Overall	-	-	-
Adults	-	-	-
Pediatric	-	-	-